An intermediate effect size variant in <i>UMOD</i> confers risk for chronic kidney disease
Eric Olinger(Cliniques Universitaires Saint-Luc), Olivier Devuyst(Cliniques Universitaires Saint-Luc), Kendrah Kidd(Wake Forest University), Patrick Hofmann(University of Zurich), Elhussein A. Elhassan(Beth Israel Deaconess Medical Center), Céline Schaeffer, Andreas D. Kistler(Kantonsspital Frauenfeld), John A. Sayer(Newcastle University), Guglielmo Schiano(University of Zurich), Luca Rampoldi(Vita-Salute San Raffaele University), Ian Wilson(Newcastle University), Daniel G. Fuster(University of Bern), Inès Dufour(Cliniques Universitaires Saint-Luc), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anna Köttgen(University of Freiburg), Anthony J. Bleyer(Wake Forest University), Peter J. Conlon(Botsford Hospital), Elena Pasqualetto, Stanislav Kmoch(Charles University), Michael S. Wiesener(MSB Medical School Berlin), Yurong Cheng(University of Freiburg), Holly Mabillard(Newcastle upon Tyne Hospitals NHS Foundation Trust)
Cited by 2
Related Papers
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2005|3.9k
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
|New England Journal of Medicine|2006|2.1k
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
|Kidney International|2007|1.5k
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
|American Journal of Transplantation|2009|1.5k